This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Shionogi Company Limited. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Nao Matsuoka: Innovator in Pharmaceutical Composition
Introduction
Nao Matsuoka is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of stable compositions for cephalosporin antibiotics. His work is essential in enhancing the efficacy and stability of pharmaceutical products.
Latest Patents
Matsuoka holds a patent for a preparation containing cephalosporin having a catechol moiety. The patent describes a stable pharmaceutical composition that includes a compound represented by a specific formula, its pharmaceutically acceptable salt, or a solvate thereof. The composition is prepared by combining this compound with selected alkali metal chlorides, alkaline earth metal chlorides, transition metal chlorides, magnesium chloride, and sugar or sugar alcohol. This innovative approach aims to improve the stability and effectiveness of cephalosporin-based medications.
Career Highlights
Nao Matsuoka is associated with Shionogi Company Limited, a prominent pharmaceutical company known for its research and development in innovative healthcare solutions. His work at Shionogi has allowed him to focus on creating advanced pharmaceutical formulations that address critical medical needs.
Collaborations
Matsuoka collaborates with talented professionals in his field, including Natsuko Kojima and Hidenori Kawasaki. These collaborations enhance the research and development process, leading to more effective pharmaceutical solutions.
Conclusion
Nao Matsuoka's contributions to pharmaceutical innovation, particularly in the area of cephalosporin compositions, highlight his role as a key inventor in the industry. His work continues to impact the development of stable and effective medications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
